Clements DR - Search Results

1

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Pol JG, et al. Among authors: clements dr. Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Oncoimmunology. 2018. PMID: 30524901 Free PMC article. Review.

2

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.

Gujar S, Dielschneider R, Clements D, Helson E, Shmulevitz M, Marcato P, Pan D, Pan LZ, Ahn DG, Alawadhi A, Lee PW. Gujar S, et al. Mol Ther. 2013 Feb;21(2):338-47. doi: 10.1038/mt.2012.228. Epub 2012 Nov 13. Mol Ther. 2013. PMID: 23299799 Free PMC article.

3

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.

Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW. Gujar SA, et al. Br J Cancer. 2014 Jan 7;110(1):83-93. doi: 10.1038/bjc.2013.695. Epub 2013 Nov 26. Br J Cancer. 2014. PMID: 24281006 Free PMC article.

4

The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Pan LZ, Ahn DG, Sharif T, Clements D, Gujar SA, Lee PW. Pan LZ, et al. Cell Cycle. 2014;13(6):1041-8. doi: 10.4161/cc.28128. Epub 2014 Feb 7. Cell Cycle. 2014. PMID: 24552824 Free PMC article.

5

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses.

Gujar SA, Clements D, Lee PW. Gujar SA, et al. Oncoimmunology. 2014 Jan 1;3(1):e27622. doi: 10.4161/onci.27622. Epub 2014 Jan 6. Oncoimmunology. 2014. PMID: 24804161 Free PMC article.

6

Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.

Mathenge EG, Dean CA, Clements D, Vaghar-Kashani A, Photopoulos S, Coyle KM, Giacomantonio M, Malueth B, Nunokawa A, Jordan J, Lewis JD, Gujar SA, Marcato P, Lee PW, Giacomantonio CA. Mathenge EG, et al. Neoplasia. 2014 Nov 20;16(11):950-60. doi: 10.1016/j.neo.2014.09.004. eCollection 2014 Nov. Neoplasia. 2014. PMID: 25425969 Free PMC article.

7

Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.

Clements DR, Sterea AM, Kim Y, Helson E, Dean CA, Nunokawa A, Coyle KM, Sharif T, Marcato P, Gujar SA, Lee PW. Clements DR, et al. J Immunol. 2015 May 1;194(9):4397-412. doi: 10.4049/jimmunol.1402132. Epub 2015 Mar 30. J Immunol. 2015. PMID: 25825443

8

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.

Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA, Lee PW. Kim Y, et al. Among authors: clements dr. Viruses. 2015 Dec 9;7(12):6506-25. doi: 10.3390/v7122953. Viruses. 2015. PMID: 26690204 Free PMC article. Review.

9

All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy.

Clements DR, Kim Y, Gujar SA, Lee PW. Clements DR, et al. Oncoimmunology. 2015 Jun 5;5(1):e1057674. doi: 10.1080/2162402X.2015.1057674. eCollection 2016. Oncoimmunology. 2015. PMID: 26942069 Free PMC article.

10

Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.

Coyle KM, Murphy JP, Vidovic D, Vaghar-Kashani A, Dean CA, Sultan M, Clements D, Wallace M, Thomas ML, Hundert A, Giacomantonio CA, Helyer L, Gujar SA, Lee PW, Weaver IC, Marcato P. Coyle KM, et al. Oncotarget. 2016 Jul 12;7(28):44096-44112. doi: 10.18632/oncotarget.9858. Oncotarget. 2016. PMID: 27286452 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

46 results

Search Page